Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Armuzzi

Showing results (71-80 of 94) with videos related to

Pageof 10
Sort By:
Tissue Antigens|October 24, 2002
High resolution MIC genotyping: design and application to the investigation of inflammatory bowel disease susceptibilityT Ahmad, S E Marshall, K Mulcahy-Hawes, et al.
International Journal of Immunopathology and Pharmacology|April 30, 2014
anti-TNF agents as therapeutic choice in immune-mediated inflammatory diseases: focus on adalimumabA Armuzzi, P Lionetti, C Blandizzi, et al.
International Journal of Immunopathology and Pharmacology|April 30, 2014
The role of tumour necrosis factor in the pathogenesis of immune-mediated diseasesC Blandizzi, P Gionchetti, A Armuzzi, et al.
Journal of Crohn'S & Colitis|June 8, 2012
Immune response to influenza A/H1N1 vaccine in inflammatory bowel disease patients treated with anti TNF-α agents: effects of combined therapy with immunosuppressantsG Andrisani, D Frasca, M Romero, et al.
International Journal of Immunopathology and Pharmacology|April 30, 2014
Adalimumab in the treatment of immune-mediated diseasesG Lapadula, A Marchesoni, A Armuzzi, et al.
Alimentary Pharmacology & Therapeutics|August 4, 2015
Paradoxical psoriasis in a large cohort of patients with inflammatory bowel disease receiving treatment with anti-TNF alpha: 5-year follow-up studyD Pugliese, L Guidi, P M Ferraro, et al.
Alimentary Pharmacology & Therapeutics|August 19, 2007
Infliximab in severe ulcerative colitis: short-term results of different infusion regimens and long-term follow-upA Kohn, M Daperno, A Armuzzi, et al.
Italian Journal of Gastroenterology and Hepatology|March 17, 1999
New concepts concerning management of Helicobacter pylori infection: 2 years after the Maastricht Consensus ReportG Gasbarrini, P Malfertheiner, M Deltenre, et al.
Frontiers in Immunology|January 30, 2023
Case report: Dupilumab treatment improved type 2 disorders in a patient with IPEX syndrome diagnosisC Caruso, L Laterza, C R Settanni, et al.
Alimentary Pharmacology & Therapeutics|May 16, 2006
Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitisM A Zocco, L Zileri dal Verme, F Cremonini, et al.
Pageof 10

Showing results (71-80 of 94) with videos related to

Sort By:
Pageof 10
Tissue Antigens|October 24, 2002
High resolution MIC genotyping: design and application to the investigation of inflammatory bowel disease susceptibilityT Ahmad, S E Marshall, K Mulcahy-Hawes, et al.
International Journal of Immunopathology and Pharmacology|April 30, 2014
anti-TNF agents as therapeutic choice in immune-mediated inflammatory diseases: focus on adalimumabA Armuzzi, P Lionetti, C Blandizzi, et al.
International Journal of Immunopathology and Pharmacology|April 30, 2014
The role of tumour necrosis factor in the pathogenesis of immune-mediated diseasesC Blandizzi, P Gionchetti, A Armuzzi, et al.
Journal of Crohn'S & Colitis|June 8, 2012
Immune response to influenza A/H1N1 vaccine in inflammatory bowel disease patients treated with anti TNF-α agents: effects of combined therapy with immunosuppressantsG Andrisani, D Frasca, M Romero, et al.
International Journal of Immunopathology and Pharmacology|April 30, 2014
Adalimumab in the treatment of immune-mediated diseasesG Lapadula, A Marchesoni, A Armuzzi, et al.
Alimentary Pharmacology & Therapeutics|August 4, 2015
Paradoxical psoriasis in a large cohort of patients with inflammatory bowel disease receiving treatment with anti-TNF alpha: 5-year follow-up studyD Pugliese, L Guidi, P M Ferraro, et al.
Alimentary Pharmacology & Therapeutics|August 19, 2007
Infliximab in severe ulcerative colitis: short-term results of different infusion regimens and long-term follow-upA Kohn, M Daperno, A Armuzzi, et al.
Italian Journal of Gastroenterology and Hepatology|March 17, 1999
New concepts concerning management of Helicobacter pylori infection: 2 years after the Maastricht Consensus ReportG Gasbarrini, P Malfertheiner, M Deltenre, et al.
Frontiers in Immunology|January 30, 2023
Case report: Dupilumab treatment improved type 2 disorders in a patient with IPEX syndrome diagnosisC Caruso, L Laterza, C R Settanni, et al.
Alimentary Pharmacology & Therapeutics|May 16, 2006
Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitisM A Zocco, L Zileri dal Verme, F Cremonini, et al.
Pageof 10